FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944588091> ?p ?o ?g. }

• W2944588091 endingPage "3334" @default.
• W2944588091 startingPage "3326" @default.
• W2944588091 abstract "We evaluated safety and immunogenicity of the first mRNA vaccines against potentially pandemic avian H10N8 and H7N9 influenza viruses. Two randomized, placebo-controlled, double-blind, phase 1 clinical trials enrolled participants between December 2015 and August 2017 at single centers in Germany (H10N8) and USA (H7N9). Healthy adults (ages 18–64 years for H10N8 study; 18–49 years for H7N9 study) participated. Participants received vaccine or placebo in a 2-dose vaccination series 3 weeks apart. H10N8 intramuscular (IM) dose levels of 25, 50, 75, 100, and 400 µg and intradermal dose levels of 25 and 50 µg were evaluated. H7N9 IM 10-, 25-, and 50-µg dose levels were evaluated; 2-dose series 6 months apart was also evaluated. Primary endpoints were safety (adverse events) and tolerability. Secondary immunogenicity outcomes included humoral (hemagglutination inhibition [HAI], microneutralization [MN] assays) and cell-mediated responses (ELISPOT assay). H10N8 and H7N9 mRNA IM vaccines demonstrated favorable safety and reactogenicity profiles. No vaccine-related serious adverse event was reported. For H10N8 (N = 201), 100-µg IM dose induced HAI titers ≥ 1:40 in 100% and MN titers ≥ 1:20 in 87.0% of participants. The 25-µg intradermal dose induced HAI titers > 1:40 in 64.7% of participants compared to 34.5% of participants receiving the IM dose. For H7N9 (N = 156), IM doses of 10, 25, and 50 µg achieved HAI titers ≥ 1:40 in 36.0%, 96.3%, and 89.7% of participants, respectively. MN titers ≥ 1:20 were achieved by 100% in the 10- and 25-µg groups and 96.6% in the 50-µg group. Seroconversion rates were 78.3% (HAI) and 87.0% (MN) for H10N8 (100 µg IM) and 96.3% (HAI) and 100% (MN) in H7N9 (50 µg). Significant cell-mediated responses were not detected in either study. The first mRNA vaccines against H10N8 and H7N9 influenza viruses were well tolerated and elicited robust humoral immune responses. ClinicalTrials.gov NCT03076385 and NCT03345043." @default.
• W2944588091 created "2019-05-16" @default.
• W2944588091 creator A5001488467 @default.
• W2944588091 creator A5002383549 @default.
• W2944588091 creator A5023726217 @default.
• W2944588091 creator A5025172411 @default.
• W2944588091 creator A5031918109 @default.
• W2944588091 creator A5035351445 @default.
• W2944588091 creator A5037371315 @default.
• W2944588091 creator A5038751078 @default.
• W2944588091 creator A5039263943 @default.
• W2944588091 creator A5040001998 @default.
• W2944588091 creator A5064685931 @default.
• W2944588091 creator A5078223339 @default.
• W2944588091 creator A5082529315 @default.
• W2944588091 creator A5088917458 @default.
• W2944588091 date "2019-05-01" @default.
• W2944588091 modified "2023-10-15" @default.
• W2944588091 title "mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials" @default.
• W2944588091 cites W1943976721 @default.
• W2944588091 cites W1964649828 @default.
• W2944588091 cites W1983534231 @default.
• W2944588091 cites W1995580450 @default.
• W2944588091 cites W1996326524 @default.
• W2944588091 cites W2033043561 @default.
• W2944588091 cites W2053330025 @default.
• W2944588091 cites W2062499965 @default.
• W2944588091 cites W2106173155 @default.
• W2944588091 cites W2107587363 @default.
• W2944588091 cites W2110949543 @default.
• W2944588091 cites W2114581239 @default.
• W2944588091 cites W2117365839 @default.
• W2944588091 cites W2120345586 @default.
• W2944588091 cites W2120350078 @default.
• W2944588091 cites W2125241192 @default.
• W2944588091 cites W2152076728 @default.
• W2944588091 cites W2170155793 @default.
• W2944588091 cites W2171890935 @default.
• W2944588091 cites W2291593655 @default.
• W2944588091 cites W2464338232 @default.
• W2944588091 cites W2587850379 @default.
• W2944588091 cites W2609075891 @default.
• W2944588091 cites W2621236801 @default.
• W2944588091 cites W2738515079 @default.
• W2944588091 cites W2741065425 @default.
• W2944588091 cites W2745973480 @default.
• W2944588091 cites W2758606222 @default.
• W2944588091 cites W2765398298 @default.
• W2944588091 doi "https://doi.org/10.1016/j.vaccine.2019.04.074" @default.
• W2944588091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31079849" @default.
• W2944588091 hasPublicationYear "2019" @default.
• W2944588091 type Work @default.
• W2944588091 sameAs 2944588091 @default.
• W2944588091 citedByCount "302" @default.
• W2944588091 countsByYear W29445880912019 @default.
• W2944588091 countsByYear W29445880912020 @default.
• W2944588091 countsByYear W29445880912021 @default.
• W2944588091 countsByYear W29445880912022 @default.
• W2944588091 countsByYear W29445880912023 @default.
• W2944588091 crossrefType "journal-article" @default.
• W2944588091 hasAuthorship W2944588091A5001488467 @default.
• W2944588091 hasAuthorship W2944588091A5002383549 @default.
• W2944588091 hasAuthorship W2944588091A5023726217 @default.
• W2944588091 hasAuthorship W2944588091A5025172411 @default.
• W2944588091 hasAuthorship W2944588091A5031918109 @default.
• W2944588091 hasAuthorship W2944588091A5035351445 @default.
• W2944588091 hasAuthorship W2944588091A5037371315 @default.
• W2944588091 hasAuthorship W2944588091A5038751078 @default.
• W2944588091 hasAuthorship W2944588091A5039263943 @default.
• W2944588091 hasAuthorship W2944588091A5040001998 @default.
• W2944588091 hasAuthorship W2944588091A5064685931 @default.
• W2944588091 hasAuthorship W2944588091A5078223339 @default.
• W2944588091 hasAuthorship W2944588091A5082529315 @default.
• W2944588091 hasAuthorship W2944588091A5088917458 @default.
• W2944588091 hasBestOaLocation W29445880911 @default.
• W2944588091 hasConcept C126322002 @default.
• W2944588091 hasConcept C159047783 @default.
• W2944588091 hasConcept C159654299 @default.
• W2944588091 hasConcept C182072434 @default.
• W2944588091 hasConcept C197934379 @default.
• W2944588091 hasConcept C203014093 @default.
• W2944588091 hasConcept C22070199 @default.
• W2944588091 hasConcept C2522874641 @default.
• W2944588091 hasConcept C2776090121 @default.
• W2944588091 hasConcept C2777704310 @default.
• W2944588091 hasConcept C2778375690 @default.
• W2944588091 hasConcept C2779053233 @default.
• W2944588091 hasConcept C2780689484 @default.
• W2944588091 hasConcept C2780868878 @default.
• W2944588091 hasConcept C32611913 @default.
• W2944588091 hasConcept C71924100 @default.
• W2944588091 hasConcept C8891405 @default.
• W2944588091 hasConceptScore W2944588091C126322002 @default.
• W2944588091 hasConceptScore W2944588091C159047783 @default.
• W2944588091 hasConceptScore W2944588091C159654299 @default.
• W2944588091 hasConceptScore W2944588091C182072434 @default.
• W2944588091 hasConceptScore W2944588091C197934379 @default.
• W2944588091 hasConceptScore W2944588091C203014093 @default.

• next